Related references
Note: Only part of the references are listed.A Pituitary Society update to acromegaly management guidelines
Maria Fleseriu et al.
PITUITARY (2021)
Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints
Craig Edward Stiles et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Predictors of postoperative biochemical remission in acromegaly
Shun Yao et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
Maria Fleseriu et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands
Luiz Eduardo Wildemberg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study
Eva C. Coopmans et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
New and emerging pharmacological treatment options for acromegaly
Ximene Antunes et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors
Sunita M. C. De Sousa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
COMPARATIVE EFFICACY OF MEDICAL TREATMENT FOR ACROMEGALY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INTEGRATED RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES
Nidan Qiao et al.
ENDOCRINE PRACTICE (2020)
Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry
U. J. Knappe et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Pituitary-Tumor Endocrinopathies
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
Stephan Petersenn et al.
PITUITARY (2020)
MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands
Brandon P. Galm et al.
PITUITARY (2020)
Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality
Daniela Esposito et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly
Eva C Coopmans et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review
Nidhi Agrawal et al.
PITUITARY (2020)
miR-34a is upregulated inAIP-mutated somatotropinomas and promotes octreotide resistance
Eva-Maria Bogner et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
Susan L. Samson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
E-cadherin expression is associated with somatostatin analogue response in acromegaly
Eva Venegas-Moreno et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression
Ammar Muhammad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study
Philippe Caron et al.
ENDOCRINE (2019)
Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study
Vivien Bonert et al.
PITUITARY (2018)
The comprehensive impact on human body induced by resolution of growth hormone excess
Zhaoyun Zhang et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature
Jakob Dal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Genomic Alterations and Complex Subclonal Architecture in Sporadic GH-Secreting Pituitary Adenomas
Mirella Hage et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
IGF1 receptor signaling pathways
Fumihiko Hakuno et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2018)
Silent somatotroph pituitary adenomas: an update
Fabienne Langlois et al.
PITUITARY (2018)
Growth Hormone Research Society perspective on biomarkers of GH action in children and adults
Gudmundur Johannsson et al.
ENDOCRINE CONNECTIONS (2018)
Automatic Detection of Acromegaly From Facial Photographs Using Machine Learning Methods
Xiangyi Kong et al.
EBIOMEDICINE (2018)
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
Thomas Guenther et al.
PHARMACOLOGICAL REVIEWS (2018)
Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY
Michael Buchfelder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
The surgical treatment of acromegaly
Michael Buchfelder et al.
PITUITARY (2017)
A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
S. E. Franck et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors
Harish Babu et al.
NEUROSURGERY (2017)
Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly
Rudolf Fahlbusch et al.
PITUITARY (2017)
Biochemical investigations in diagnosis and follow up of acromegaly
Katharina Schilbach et al.
PITUITARY (2017)
Updates in outcomes of stereotactic radiation therapy in acromegaly
Monica Livia Gheorghiu
PITUITARY (2017)
Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications
Ching-Jen Chen et al.
ACTA NEUROCHIRURGICA (2017)
The 2017 World Health Organization classification of tumors of the pituitary gland: a summary
M. Beatriz S. Lopes
ACTA NEUROPATHOLOGICA (2017)
Mortality in acromegaly: a 20-year follow-up study
Elina Ritvonen et al.
ENDOCRINE-RELATED CANCER (2016)
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
Donato Iacovazzo et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
New therapeutic agents for acromegaly
Shlomo Melmed
NATURE REVIEWS ENDOCRINOLOGY (2016)
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly
Federico Gatto et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Growth hormone signaling pathways
Christin Carter-Su et al.
GROWTH HORMONE & IGF RESEARCH (2016)
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly
Ansgar Heck et al.
ENDOCRINE (2016)
SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY
Jeremy R. Anthony et al.
ENDOCRINE PRACTICE (2015)
X-linked acrogigantism syndrome: clinical profile and therapeutic responses
Albert Beckers et al.
ENDOCRINE-RELATED CANCER (2015)
A Structural and Functional Acromegaly Classification
Daniel Cuevas-Ramos et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Endoscopic versus microscopic approach for surgical treatment of acromegaly
Hussein Fathalla et al.
NEUROSURGICAL REVIEW (2015)
Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort
Caroline Sievers et al.
PITUITARY (2015)
Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis
Z. A. Efstathiadou et al.
PITUITARY (2015)
Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels
Michael Droste et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Acromegaly and McCune-Albright Syndrome
Sylvie Salenave et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
Philippe J. Caron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Stereotactic Radiosurgery for Acromegaly
Cheng-Chia Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
Andrew J. Brooks et al.
SCIENCE (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas
Sarah Larkin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern
Leandro Kasuki et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
Jessica Brzana et al.
PITUITARY (2013)
Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
Ansgar Heck et al.
CLINICAL ENDOCRINOLOGY (2012)
AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
Leandro Kasuki et al.
ENDOCRINE-RELATED CANCER (2012)
Predicting Long-term Remission by Measuring Immediate Postoperative Growth Hormone Levels and Oral Glucose Tolerance Test in Acromegaly
Eui Hyun Kim et al.
NEUROSURGERY (2012)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Clinical Utility of Insulin-Like Growth Factor 1 and 2; Determination by High Resolution Mass Spectrometry
Cory Bystrom et al.
PLOS ONE (2012)
Clinical laboratory indices in the treatment of acromegaly
David R. Clemmons
CLINICA CHIMICA ACTA (2011)
Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays
David R. Clemmons
CLINICAL CHEMISTRY (2011)
Limited utility of oral glucose tolerance test in biochemically active acromegaly
Antonio Ribeiro-Oliveira et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
A Novel Approach to the Detection of Acromegaly: Accuracy of Diagnosis by Automatic Face Classification
Harald J. Schneider et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed
Tirissa J. Reid et al.
CLINICAL ENDOCRINOLOGY (2010)
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study
Ming Shen et al.
ENDOCRINE JOURNAL (2010)
Acromegaly without Imaging Evidence of Pituitary Adenoma
Russell R. Lonser et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure
Manel Puig-Domingo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study
Adrian F. Daly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
ZAC1 target genes and pituitary tumorigenesis
Marily Theodoropoulou et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Ghrelin and growth hormone: Story in reverse
Ralf M. Nass et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly
Marily Theodoropoulou et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Low levels of Raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment
Stine Lyngvi Fougner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Radiation therapy in acromegaly
Helen A. Shih et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2008)
Long-term efficacy and safety of combined treatment of somatostatin analogs and Pegvisomant in acromegaly
Sebastian J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression
M Theodoropoulou et al.
CANCER RESEARCH (2006)
The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly
S Bhayana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant
AL Barkan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Discovery and mechanism of action of pegvisomant
JJ Kopchick
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2
KC Leung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma.
F Beuschlein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
